Clinical Trials

The Tumor Immunotherapy Program has a number of studies that are currently recruiting patients. For information about how to be referred to one of these studies, please contact us.

Currently Recruiting

  • GSK208750

    Long-Term Follow-Up (LTFU) of Participants Treated with GSK Adoptive Cell Therapies

    Eligible Tumour Type(s): Solid Cancer
    Principal Investigator: Dr. Adrian Sacher
    NCT#: NCT03391778

    https://www.clinicaltrials.gov/ct2/show/NCT03391778

  • SQZ-PBMC-HPV-101

    A Phase 1, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of SQZ-PBMC-HPV as Monotherapy and in Combination With Atezolizumab in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

    Eligible Tumour Type(s): Solid Cancer
    Principal Investigator: Dr. Neesha Dhani
    NCT#: NCT04084951

    https://clinicaltrials.gov/ct2/show/NCT04084951

  • CRSP-ONC-003

    A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Advanced, Relapsed or Refractory Renal Cell Carcinoma With Clear Cell Differentiation

    Eligible Tumour Type(s): Renal Cell Carcinoma
    Principal Investigator: Dr. Adrian Sacher
    NCT#: NCT04438083

    https://clinicaltrials.gov/ct2/show/NCT04438083

  • TCR2-18-01

    A Phase 1/2 Single Arm Open-Label Clinical Trial of Tc-210 T Cells In Patients with Advanced Mesothelin-Expressing Cancer

    Eligible Tumour Type(s): Solid Cancer
    Principal Investigator: Dr. Marcus Butler
    NCT#: NCT03907852

    https://clinicaltrials.gov/ct2/show/NCT03907852

  • IOV-LUN-202

    A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer 

    Eligible Tumour Type(s): Non-small Cell Lung Cancer
    Principal Investigator: Dr. Adrian Sacher
    NCT#: NCT04614103

    https://clinicaltrials.gov/ct2/show/NCT04614103

  • TAC01-HER2-03

    A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC T Cells Targeting HER2 in Relapsed or Refractory Solid Tumors (TACTIC-2) 

    Eligible Tumour Type(s): Solid Cancer
    Principal Investigator: Dr. Adrian Sacher
    NCT#: NCT04727151

    https://clinicaltrials.gov/ct2/show/NCT04727151

Closed Recruiting

  • 1301-02

    Phase 1b Study of NY-ESO-1 specific TCR gene transduced autologous T lymphocytes in patients with solid tumors

    Eligible Tumour Type(s): Solid Cancer
    Sponsor: In-house (in collaboration with Takara Bio Inc)
    Principal Investigator: Marcus Butler
    NCT#: NCT02869217

    https://clinicaltrials.gov/ct2/show/NCT02869217

  • TILs-003-Meso

    Phase I/II study evaluating the infusion of tumor-infiltrating lymphocytes (TILs) and low-dose interleukin-2 (IL-2) therapy following a preparative regimen of non-myeloablative lymphodepletion using cyclophosphamide and fludarabine in patients with malignant pleural mesothelioma)

    Eligible Tumour Type(s): Malignant Pleural Mesothelioma
    Sponsor: In-House
    Principal Investigator: Dr. Marcus Butler
    NCT#: NCT02414945

    https://clinicaltrials.gov/ct2/show/NCT02414945?term=TILs-003-Meso&rank=1

  • INSPIRE

    INvestigator-initiated Phase II Study of pembrolizumab immunological response evaluation

    Eligible Tumour Type(s): Metastatic Melanoma, Ovarian Cancer, Solid Cancer, Squamous Cell Cancer of the Head and Neck, Triple Negative Breast Cancer
    Sponsor: In-House
    Principal Investigator: Dr. Lillian Siu
    NCT#: NCT02644369

    https://clinicaltrials.gov/ct2/show/NCT02644369

  • ACTIVATE

    Phase Ib trial of pembrolizumab administered in combination or following adoptive cell therapy: A multiple cohort study

    Eligible Tumour Type(s): Metastatic Melanoma, Ovarian Cancer
    Sponsor: In-House
    Principal Investigator: Dr. Marcus Butler
    NCT#: NCT02811497

    https://clinicaltrials.gov/ct2/show/NCT03158935

Pages